AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

AstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.

AstraZeneca has been urging sports fans to “Get Body Checked Against Cancer” in a campaign launched in collaboration with the ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

AstraZeneca PLC ADR closed 13.33% below its 52-week high of $87.68, which the company achieved on August 30th.

Limited or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' ...

Learn more about whether Corcept Therapeutics Incorporated or HUTCHMED (China) Limited is a better investment based on AAII's ...

AstraZeneca PLC ADR closed 11.89% below its 52-week high of $87.68, which the company reached on August 30th.

Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.